

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3768975

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	ADVANCED BIO-TECHNOLOGIES, INC.	02/29/2016
RECEIVING PARTY DATA		
Name:	BANK OF SCOTLAND PLC	
Street Address:	150 FOUNTAINBRIDGE	
City:	EDINBURGH	
State/Country:	UNITED KINGDOM	
Postal Code:	EH3 9PE	
PROPERTY NUMBERS Total: 6		
Property Type	Number	
Patent Number:	8802133	
Patent Number:	5741509	
Patent Number:	8263114	
Patent Number:	8021683	
Application Number:	12487489	
Application Number:	14322584	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	brobinson@sandw.com	
Correspondent Name:	SULLIVAN & WORCESTER LLP	
Address Line 1:	ONE POST OFFICE SQUARE	
Address Line 4:	BOSTON, MASSACHUSETTS 02109	
NAME OF SUBMITTER:	B. ROBINSON	
SIGNATURE:	/B. Robinson/	
DATE SIGNED:	03/04/2016	
	This document serves as an Oath/Declaration (37 CFR 1.63).	
Total Attachments: 7		
source=B1971454#page1.tif		

source=B1971454#page2.tif

source=B1971454#page3.tif

source=B1971454#page4.tif

source=B1971454#page5.tif

source=B1971454#page6.tif

source=B1971454#page7.tif

PATENT

REEL: 037894 FRAME: 0238

INTELLECTUAL PROPERTY SECURITY AGREEMENT


INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of

2. This security interest is granted in conjunction with the security interest granted to Security Agent under the Security Agreement. The rights and remedies of Security Agent with respect to the security interest granted hereby are in addition to those set forth in the Security Agreement, Credit Agreement and other Finance Documents, and those which are now or hereafter available to Security Agent as a matter of law or equity. Each right, power and remedy of Security Agent provided for herein or in the Security Agreement, Credit Agreement or other Finance Documents, or now or hereafter existing at law or in equity, shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Security Agent of any one or more of the rights, powers or remedies provided for in this Agreement, the Security Agreement, the Credit Agreement or other Finance Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person of any or all other rights, power or remedies. This Agreement shall constitute a Finance Document as defined in the Credit Agreement.

This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif") format shall be effective as delivery of a manually executed counterpart of this Agreement.


[Signature Page Follows]

IN WITNESS WHEREOF, Grantor has caused this Agreement to be duly executed as of the date first above written.

c/o Alliance Pharma plc Avonbridge House, Bath Road Chippenham, Wiltshire SN15 2BB Fax: 01249 466 977 Attention: John Dawson, President	ADVANCED BIO-TECHNOLOGIES, INC. By  Name: John Dawson Title: President
Accepted: BANK OF SCOTLAND PLC, as Security Agent By _____ Name: Title:	Agency - Specialist Lending Services Lloyds Bank Commercial Banking 150 Fountainbridge Edinburgh EH3 9PE Attention: Glenn Drysdale and Iain Brown Fax: +44 (0) 131 347 7229

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, Grantor has caused this Agreement to be duly executed as of the date first above written.

c/o Alliance Pharma plc Avonbridge House, Bath Road Chippenham, Wiltshire SN15 2BB Fax: 01249 466 977 Attention: John Dawson, President	ADVANCED BIO-TECHNOLOGIES, INC. By _____ Name: John Dawson Title: President
Accepted: BANK OF SCOTLAND PLC, as Security Agent By  Name: Iain Brown Title: Associate Director	Agency - Specialist Lending Services Lloyds Bank Commercial Banking 150 Fountainbridge Edinburgh EH3 9PE Attention: Glenn Drysdale and Iain Brown Fax: +44 (0) 131 347 7229

[Signature Page to Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents and Patent Applications

<u>Title</u>	<u>Patent No.</u>	<u>Application No.</u>	<u>Owner</u>	<u>Inventor</u>	<u>Filing Date</u>	<u>Jurisdiction</u>
Silicone scar treatment preparation		12/487,489	Advanced Bio-Technologies, Inc.	Paul Guilbaud	6/18/2009	US
Silicone scar treatment preparation	8802133	13/548,899	Advanced Bio-Technologies, Inc.	Paul Guilbaud	7/13/2013	US
Silicone scar treatment preparation		14/322,584	Advanced Bio-Technologies, Inc.	Paul Guilbaud	7/2/2014	US
Silicone wound dressing	5741509	08/703,324	Advanced Bio-Technologies, Inc.	Jack Kushner	8/26/1996	US
Topical pharmaceutical formulation	8263114	10/480,719	Advanced Bio-Technologies, Inc.	Alvin Berlat	7/23/2002	US
Wound dressing	8021683	10/479,877	Advanced Bio-Technologies, Inc.	Alvin Berlat	5/3/2004	US

EXHIBIT C

Trademarks

<u>Jurisdiction of Registration</u>	<u>Trademark</u>	<u>Trademark Registration Number(s)</u>	<u>Registration Date</u>
United States of America	Kelo-Cote ¹	3166390	October 31, 2006
United States of America	Kelo-Cote ²	2633724	October 15, 2002

¹ Pursuant to that certain License, Rights and Supply Agreement, dated December 8, 2011, between Advanced Bio-Technologies, Inc. ("ABT") and SOS Brands, Inc. d/b/a Enaltus ("SOS"), ABT granted SOS an exclusive license to (i) the rights under the Kelo-Cote product patents to distribute the Kelo-Cote products and any new products under the Kelo-Cote product trademark, logo and name, (ii) all related assets described in the Kelo-Cote License Agreement, including the Kelo-Cote product intellectual property and the right to grant sub-licenses, (iii) manufacture and supply (and to have manufactured and supplied) the Kelo-Cote products in the United States, and (iv) to use the Kelo-Cote product trademark on the products in appropriate formulations and under associated branding guidelines.

² See footnote 1.